

## **RHYTHM BIOSCIENCES LIMITED: 2025 - A Year in Review**

Dear Shareholders,

On behalf of the Board of Directors and the team at Rhythm Biosciences, thank you for your continued support and confidence in our mission throughout 2025. Your commitment has been instrumental in driving our progress and enabling us to advance our transformative cancer diagnostics technologies and expand our global footprint.

This year marked a pivotal period in Rhythm's evolution as we executed on multiple strategic initiatives designed to create long-term shareholder value. 2025 saw Rhythm develop from an organisation focussed on R&D in January to the current commercially focussed business selling ColoSTAT® and geneType™.

### **Key 2025 Business Achievements Include:**

- **Strategic Acquisition and Integration of geneType™ Business:** Completed the acquisition and integration of the geneType™ predictive cancer risk assessment platform. This added a revenue-generating platform with established US infrastructure and an experienced operational team broadening the Company's activities beyond early cancer detection and into cancer risk assessment.
- **ColoSTAT® Clinical Validation:** Demonstrated conclusive performance of ColoSTAT® in patients aged 45 to 80 diagnosed with colorectal cancer, with consistent performance across both genders, further validating our blood-based screening technology.
- **US Market Expansion Partnership:** Entered several strategic marketing partnerships such as the one with Catch Bio in December 2025, providing direct access to Catch Bio's US member base for geneType™. This collaboration validates the growing market acceptance of our predictive diagnostics platform.
- **NHS England ColoSTAT® Collaboration:** Secured a landmark collaboration with The Royal Surrey NHS Foundation Trust to evaluate ColoSTAT® for potential inclusion in England's national bowel cancer screening pathway.
- **ColoSTAT® Commercial Launch:** Regulatory clearance was achieved in December 2025 paving the way for commercialisation of ColoSTAT® in the Australian market.
- **Dual-Platform Strategy Execution:** Successfully advanced both our detection platform (ColoSTAT®) and prediction platform (geneType™), positioning Rhythm as a comprehensive cancer diagnostics company addressing the full spectrum of cancer risk assessment and early detection.

These achievements reflect the disciplined execution of Rhythm's strategy, the dedication of our team, the strength of our scientific foundation, and the quality of our partnerships. The Board remains focused on careful capital management, operational delivery and the responsible progression of the Company's technology to deliver meaningful value to patients, healthcare systems, and shareholders alike.

Your continued support enables us to pursue our vision of transforming cancer diagnostics through innovation, scientific rigor, and strategic execution. We thank you for being part of the Rhythm Biosciences journey and look forward to building on this momentum in 2026. Finally, on behalf of the Board and management, we wish you a restful holiday and a wonderful New Year.

Yours sincerely,

**David Atkins**  
Chief Executive Officer  
Rhythm Biosciences Limited